GlassScriptPhysician profile
Daniel W Whitley
NPI 1043215874
$6,024.65
in general payments reported to CMS, 2019-2025
36 companies · $55.46 in 2025
The $55.46 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $554 · 2021: $1,085 · 2022: $1,336 · 2023: $1,278 · 2024: $546 · 2025: $55.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $894.31 | 2019-2025 | Farxiga, Breztri, Tezspire |
| Pfizer INC. | $593.68 | 2019-2025 | |
| Lilly USA, LLC | $496.76 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $478.29 | 2019-2024 | Ubrelvy, Vraylar |
| Merck Sharp & Dohme LLC | $462.61 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $355.31 | 2019-2023 | |
| Novo Nordisk INC | $339.34 | 2019-2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $338.84 | 2019-2023 | Myrbetriq, Veozah |
| Abbott Laboratories | $303.59 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $227.47 | 2020-2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.31 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.78 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $171.27 | 2019-2022 | |
| Amgen INC. | $112.59 | 2019-2025 | Tezspire |
| Evoke Pharma, INC. | $91.92 | 2022-2023 | Gimoti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $91.91 | 2019-2023 | Aralast |
| Sumitomo Pharma America, INC. | $90.03 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $85.80 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $80.24 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.77 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $52.68 | 2023 | Rexulti |
| Jazz Pharmaceuticals INC. | $41.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $40.09 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.79 | 2021 | |
| Collegium Pharmaceutical, INC. | $28.88 | 2021 | |
| Exact Sciences Corporation | $21.00 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $18.99 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.57 | 2024 | Crysvita |
| Almatica Pharma LLC | $17.10 | 2022 | |
| Allergan, INC. | $16.67 | 2020 | |
| Glaxosmithkline, LLC. | $15.12 | 2023 | Shingrix |
| Alexion Pharmaceuticals, INC. | $14.65 | 2022 | |
| Eisai INC. | $14.52 | 2021 | |
| Neurocrine Biosciences, INC. | $14.47 | 2022 | |
| Acadia Pharmaceuticals INC | $13.34 | 2021 | |
| Livanova USA, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Whitley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.